• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Relenza (zanamivir for inhalation)

Health professionals are notified of important revisions to the safety labeling for Relenza. The labeling has been revised to more clearly reflect that serious respiratory adverse events have been reported in patients with or without known underlying respiratory disease, and to incorporate additional updated safety information.

[July 2000 - Letter - Glaxo Wellcome, Inc.]